Drug Profile
Human fibrinogen - Guizhou Taibang Biological Products
Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Guizhou Taibang Biological Products
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Afibrinogenaemia
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Afibrinogenaemia in China (IV, Infusion)
- 24 Nov 2015 Clinical trials in Afibrinogenaemia in China (IV)